ChromaDex Corporation (NAGE) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for ChromaDex Corporation (NAGE:NASDAQ), powered by AI.

Current Price
$4.17
P/E Ratio
19.0
Market Cap
330M
Sector
Healthcare
What is the ChromaDex Corporation stock price forecast?

ChromaDex Corporation is currently trading at $4.17. View real-time AI analysis on Alpha Lenz.

What is ChromaDex Corporation insider trading activity?

View the latest insider trading data for ChromaDex Corporation on Alpha Lenz.

What is ChromaDex Corporation's P/E ratio?

ChromaDex Corporation's P/E ratio is 19.0.

ChromaDex Corporation

NASDAQ · NAGE
$4.17-0.02(-0.48%)Market closedNASDAQ regular session 09:30–16:00 ET
Ask about ChromaDex Corporation's future dividend policy...
Alpha Chat Insight

ChromaDex Corporation trades at a P/E of 19.0 (fair value) with strong ROE of 28.3%.

Ask for details

Company Overview

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceuticalgrade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also offers the supply of phytochemical reference standards and other research and development services. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

CEOMr. Robert N. Fried
SectorHealthcare
IndustryBiotechnology
Employees104

Company Statistics

FY 2025

Profile

$330.17MMarket Cap
$129.42MRevenue
0.00Shares Out
104Employees

Margins

64.28%Gross
10.63%EBITDA
11.05%Operating
14.06%Pre-Tax
13.43%Net

Valuation

19.00P/E
4.31P/B
2.55EV/Sales
19.50EV/EBITDA
24.99P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

19.90%ROA
28.35%ROE
16.37%ROIC

Financial Health

$64.64MCash & Cash Equivalents
$-34.76MNet Debt
39.03%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

ChromaDex Corporation (ticker: NAGE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 104 employees. Market cap is $330M.

The current price is $4.17 with a P/E ratio of 19x and P/B of 4.31x.

ROE is 28.35% and operating margin is 11.05%. Annual revenue is $129M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
ChromaDex Corporation (Healthcare) Stock Forecast & Analysis $4.17 | Alpha Lenz